The 2024 AACR abstract title drop features several noteworthy clinical studies.

First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.

Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.

GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.

The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.